Zealand Pharma AS (CHIX:ZEALC) Change In Inventory: kr0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ZEALC Zealand Pharma AS CHIX:ZEALC
40 GF Score
Price kr295.40
! 7 Warning Signs
View Full Analysis

What is Zealand Pharma AS Change In Inventory?

Zealand Pharma AS CHIX:ZEALC 40 Change In Inventory is kr0 Mil as of Jun. 2026. GuruFocus rates CHIX:ZEALC with a GF Score™ of 40/100. The stock has 7 warning signs investors should review.

Zealand Pharma AS's change in inventory for the quarter that ended in Jun. 2026 was kr0 Mil. It means Zealand Pharma AS's inventory stayed the same from Mar. 2026 to Jun. 2026 .

Zealand Pharma AS's change in inventory for the fiscal year that ended in Dec. 2025 was kr11 Mil. It means Zealand Pharma AS's inventory declined by kr11 Mil from Dec. 2024 to Dec. 2025 .

Zealand Pharma AS's Total Inventories for the quarter that ended in Jun. 2026 was kr0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Zealand Pharma AS's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.00.

Zealand Pharma AS  (CHIX:ZEALc) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Zealand Pharma AS's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 4
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Zealand Pharma AS's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Zealand Pharma AS's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 4491
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Change In Inventory Related Terms

Zealand Pharma AS Change In Inventory Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Change In Inventory Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -52.77 18.22 9.34 -2.76 10.70

Zealand Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:ZEALC
40GF Score
Zealand Pharma AS CHIX:ZEALC
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of kr0 Mil mean?
Zealand Pharma AS (CHIX:ZEALC) has a Change In Inventory of kr0 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Change In Inventory too high?
Zealand Pharma AS's current Change In Inventory is kr0 Mil. Overall, Zealand Pharma AS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Change In Inventory compare to VRTX and REGN?
Zealand Pharma AS's Change In Inventory of kr0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Zealand Pharma AS and its competitors. Zealand Pharma AS's current Change In Inventory is kr0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (CHIX:ZEALC) has a current Change In Inventory of kr0 Mil. The current Change In Inventory is kr0 Mil. Zealand Pharma AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Zealand Pharma AS (CHIX:ZEALC), the current Change In Inventory is kr0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
40GF Score

Get the complete analysis for CHIX:ZEALC

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr295.40
Price